Aspivix raises EUR 837,800

Aspivix is developing carevix, a device intended to replace the Pozzi forceps for stabilising the cervix during gynaecological procedures. The Vaud-based medtech raised EUR 837,800 (around CHF 790,000) from 108 investors on Capital Cell as part of its Series B2 round, to expand the clinical use of carevix.

Announced on
Round
Series B
Amount
EUR 837,800
Location
Epalinges, canton of Vaud
Sector
Health & medtech

Investors

  • Capital Cell

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic